Evidence map›Paper›PMID 22496461›Full record

ArticleMolecular cancer research : MCR2012

SAP155-mediated splicing of FUSE-binding protein-interacting repressor serves as a molecular switch for c-myc gene expression.

Kazuyuki Matsushita, Toshiko Kajiwara, Mai Tamura, Mamoru Satoh, Nobuko Tanaka, Takeshi Tomonaga, Hisahiro Matsubara, Hideaki Shimada, Rei Yoshimoto, Akihiro Ito and 5 more

Open access · greenAbstract read
In one paragraph

Article in Molecular cancer research : MCR, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 26 citations in OpenAlex.

  1. International journal of molecular sciences · 2026
    Review
  2. Article
  3. RNA-binding motif protein 10 inactivates c-Myc by partnering with ribosomal proteins uL18 and uL5.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Oncotarget · 2017
    Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 2 countries.

Kazuyuki MatsushitaDepartment of Molecular Diagnosis (F8), Chiba University Graduate School of Medicine, Chiba City, Chiba 260-8670, Japan. kmatsu@faculty.chiba-u.jp
Toshiko Kajiwara
Mai Tamura
Mamoru Satoh
Nobuko Tanaka
Takeshi Tomonaga
Hisahiro Matsubara
Hideaki Shimada
Rei Yoshimoto
Akihiro Ito
Shuji Kubo
Tohru Natsume
David Levens
Minoru Yoshida
Fumio Nomura
National Institute of Advanced Industrial Science and Technology · JPToho University Omori Medical Center · JPNational Cancer Institute · USNational Institute of Biomedical Innovation, Health and Nutrition · JPRIKEN Advanced Science Institute · JPToho University · JPChiba University · JP

Funding

Mechanisms of transcription factor integration at the c-myc promoterZIASC009144 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI LEVENS, DAVID L. · 2009 to 2025
$9.5M
Mechanisms of transcription factor integration at the c-myc promoterZ01SC009144 · SC · DIVISION OF CLINICAL SCIENCES - NCI · PI LEVENS, DAVID L. · 1996 to 2008
$3.1M
Intramural NIH HHS Z01 SC009144
6 · The paper itself

Abstract

The Far UpStream Element (FUSE)-binding protein-interacting repressor (FIR), a c-myc transcriptional suppressor, is alternatively spliced removing the transcriptional repression domain within exon 2 (FIRΔexon2) in colorectal cancers. SAP155 is a subunit of the essential splicing factor 3b (SF3b) subcomplex in the spliceosome. This study aims to study the significance of the FIR-SAP155 interaction for the coordination of c-myc transcription, pre-mRNA splicing, and c-Myc protein modification, as well as to interrogate FIRΔexon2 for other functions relating to altered FIR pre-mRNA splicing. Knockdown of SAP155 or FIR was used to investigate their reciprocal influence on each other and on c-myc transcription, pre-mRNA splicing, and protein expression. Pull down from HeLa cell nuclear extracts revealed the association of FIR, FIRΔexon2, and SF3b subunits. FIR and FIRΔexon2 were coimmunoprecipitated with SAP155. FIR and FIRΔexon2 adenovirus vector (Ad-FIR and Ad-FIRΔexon2, respectively) were prepared to test for their influence on c-myc expression. FIR, SAP155, SAP130, and c-myc were coordinately upregulated in human colorectal cancer. These results reveal that SAP155 and FIR/FIRΔexon2 form a complex and are mutually upregulating. Ad-FIRΔexon2 antagonized Ad-FIR transcriptional repression of c-myc in HeLa cells. Because FIRΔexon2 still carries RRM1 and RRM2 and binding activity to FUSE, it is able to displace repression competent FIR from FUSE in electrophoretic mobility shift assays, thus thwarting FIR-mediated transcriptional repression by FUSE. Thus aberrant FIRΔexon2 production in turn sustained c-Myc expression. In conclusion, altered FIR and c-myc pre-mRNA splicing, in addition to c-Myc expression by augmented FIR/FIRΔexon2-SAP155 complex, potentially contribute to colorectal cancer development.

Indexed as

Alternative SplicingAmino Acid SequenceBase SequenceBlotting, WesternColorectal NeoplasmsExonsHCT116 CellsHEK293 CellsHeLa CellsHumansIntronsMolecular Sequence DataMutationPhosphoproteinsProtein BindingProto-Oncogene Proteins c-mycMYC protein, humanPhosphoproteinspoly-U binding splicing factor 60KDaProto-Oncogene Proteins c-mycRepressor ProteinsRibonucleoprotein, U2 Small NuclearRNA-Binding ProteinsRNA PrecursorsRNA Splicing FactorsSF3B1 protein, human

Identifiers

PMID22496461
PMCPMC7469880
OpenAlexW2140011914

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.